702 related articles for article (PubMed ID: 29452684)
1. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
[TBL] [Abstract][Full Text] [Related]
2. Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms.
Ballard C; Youakim JM; Coate B; Stankovic S
J Prev Alzheimers Dis; 2019; 6(1):27-33. PubMed ID: 30569083
[TBL] [Abstract][Full Text] [Related]
3. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C
Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563
[TBL] [Abstract][Full Text] [Related]
4. Pimavanserin: Potential Treatment For Dementia-Related Psychosis.
Cummings J; Ballard C; Tariot P; Owen R; Foff E; Youakim J; Norton J; Stankovic S
J Prev Alzheimers Dis; 2018; 5(4):253-258. PubMed ID: 30298184
[TBL] [Abstract][Full Text] [Related]
5. Trial of Pimavanserin in Dementia-Related Psychosis.
Tariot PN; Cummings JL; Soto-Martin ME; Ballard C; Erten-Lyons D; Sultzer DL; Devanand DP; Weintraub D; McEvoy B; Youakim JM; Stankovic S; Foff EP
N Engl J Med; 2021 Jul; 385(4):309-319. PubMed ID: 34289275
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: A post hoc analysis.
Ballard CG; Coate B; Abler V; Stankovic S; Foff E
Int J Geriatr Psychiatry; 2020 Nov; 35(11):1402-1408. PubMed ID: 32729631
[TBL] [Abstract][Full Text] [Related]
7. Pimavanserin: A Novel Antipsychotic for Parkinson's Disease Psychosis.
Bozymski KM; Lowe DK; Pasternak KM; Gatesman TL; Crouse EL
Ann Pharmacother; 2017 Jun; 51(6):479-487. PubMed ID: 28375643
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
9. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH
Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417
[TBL] [Abstract][Full Text] [Related]
10. Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis.
Ballard CG; Kreitzman DL; Isaacson S; Liu IY; Norton JC; Demos G; Fernandez HH; Ilic TV; Azulay JP; Ferreira JJ; Abler V; Stankovic S;
Parkinsonism Relat Disord; 2020 Aug; 77():100-106. PubMed ID: 32712560
[TBL] [Abstract][Full Text] [Related]
11. Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson's Disease Psychosis.
Isaacson SH; Coate B; Norton J; Stankovic S
J Parkinsons Dis; 2020; 10(4):1389-1396. PubMed ID: 32716320
[TBL] [Abstract][Full Text] [Related]
12. Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications.
Espay AJ; Guskey MT; Norton JC; Coate B; Vizcarra JA; Ballard C; Factor SA; Friedman JH; Lang AE; Larsen NJ; Andersson C; Fredericks D; Weintraub D
Mov Disord; 2018 Nov; 33(11):1769-1776. PubMed ID: 30387904
[TBL] [Abstract][Full Text] [Related]
13. Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe.
Bugarski-Kirola D; Arango C; Fava M; Nasrallah H; Liu IY; Abbs B; Stankovic S
Lancet Psychiatry; 2022 Jan; 9(1):46-58. PubMed ID: 34861170
[TBL] [Abstract][Full Text] [Related]
14. Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients.
Isaacson SH; Ballard CG; Kreitzman DL; Coate B; Norton JC; Fernandez HH; Ilic TV; Azulay JP; Ferreira JJ; Abler V; Stankovic S;
Parkinsonism Relat Disord; 2021 Jun; 87():25-31. PubMed ID: 33933853
[TBL] [Abstract][Full Text] [Related]
15. Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson's Disease Psychosis.
Patel N; LeWitt P; Neikrug AB; Kesslak P; Coate B; Ancoli-Israel S
Clin Neuropharmacol; 2018; 41(6):210-215. PubMed ID: 30303817
[TBL] [Abstract][Full Text] [Related]
16. Pimavanserin, a novel antipsychotic for management of Parkinson's disease psychosis.
Kianirad Y; Simuni T
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1161-1168. PubMed ID: 28817967
[TBL] [Abstract][Full Text] [Related]
17. Pimavanserin for psychosis in Parkinson's disease dementia: Subgroup analysis of the HARMONY Trial.
Weintraub D; Espay AJ; Sharma VD; Tariot PN; Abler V; Pathak S; Stankovic S
Parkinsonism Relat Disord; 2024 Feb; 119():105951. PubMed ID: 38113700
[TBL] [Abstract][Full Text] [Related]
18. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MG; Bilenberg N; Stenstrøm AD; Nyvang L; Madsen S; Werge TM; Lange T; Gluud C; Skoog M; Winkel P; Jepsen JRM; Fagerlund B; Correll CU; Fink-Jensen A
Lancet Psychiatry; 2017 Aug; 4(8):605-618. PubMed ID: 28599949
[TBL] [Abstract][Full Text] [Related]
19. Pimavanserin for the treatment of Parkinson's disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Citrome L; Norton JC; Chi-Burris K; Demos G
CNS Spectr; 2018 Jun; 23(3):228-238. PubMed ID: 29098976
[TBL] [Abstract][Full Text] [Related]
20. Safety Profile of Pimavanserin Therapy in Elderly Patients with Neurodegenerative Disease-Related Neuropsychiatric Symptoms: A Phase 3B Study.
Alva G; Cubała WJ; Berrio A; Coate B; Abler V; Pathak S
J Alzheimers Dis; 2024; 98(1):265-274. PubMed ID: 38427485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
